Differential effects of sphingosine 1-phosphate receptors on airway and vascular barrier function in the murine lung
Article
Sammani, S, Moreno-Vinasco, L, Mirzapoiazova, T et al. (2010). Differential effects of sphingosine 1-phosphate receptors on airway and vascular barrier function in the murine lung
. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 43(4), 394-402. 10.1165/rcmb.2009-0223OC
Sammani, S, Moreno-Vinasco, L, Mirzapoiazova, T et al. (2010). Differential effects of sphingosine 1-phosphate receptors on airway and vascular barrier function in the murine lung
. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 43(4), 394-402. 10.1165/rcmb.2009-0223OC
The therapeutic options for ameliorating the profound vascular permeability, alveolar flooding, and organ dysfunction that accompanies acute inflammatory lung injury (ALI) remain limited. Extending our previous finding that the intravenous administration of the sphingolipid angiogenic factor, sphingosine 1-phosphate (S1P), attenuates inflammatory lung injury and vascular permeability via ligation of S1PR1, we determine that a direct intratracheal or intravenous administration of S1P, or a selective S1P receptor (S1PR1) agonist (SEW-2871), produces highly concentration-dependent barrier-regulatory responses in the murine lung. The intratracheal or intravenous administration of S1P or SEW-2871 at < 0.3 mg/kg was protective against LPS-induced murine lung inflammation and permeability. However, intratracheal delivery of S1P at 0.5 mg/kg (for 2 h) resulted in significant alveolar-capillary barrier disruption (with a 42% increase in bronchoalveolar lavage protein), and produced rapid lethalitywhendelivered at 2 mg/kg. Despite the greater selectivity for S1PR1, intratracheally delivered SEW-2871 at 0.5 mg/ kg also resulted in significant alveolar-capillary barrier disruption, but was not lethal at 2 mg/kg. Consistent with the S1PR1 regulation of alveolar/vascular barrier function, wild-type mice pretreated with the S1PR1 inverse agonist, SB-649146, or S1PR1+/- mice exhibited reduced S1P/SEW-2871-mediated barrier protection after challenge with LPS. In contrast, S1PR2-/- knockout mice as well as mice with reduced S1PR3 expression (via silencing S1PR3-containing nanocarriers) were protected against LPS-induced barrier disruption compared with control mice. These studies underscore the potential therapeutic effects of highly selective S1PR1 receptor agonists in reducing inflammatory lung injury, and highlight the critical role of the S1P delivery route, S1PR1 agonist concentration, and S1PR1 expression in target tissues.
